Actos Settlements and Verdicts

Actos Settlements
In 2015, Takeda Pharmaceuticals agreed to fund a $2.37 billion Actos settlement to resolve thousands of cases filed over the Type 2 diabetes drug’s alleged association with bladder cancer. The accord followed a number of trials, several of which ended with multimillion verdicts in favor of plaintiffs.

Do You Qualify for the Actos Settlement?

You may qualify for compensation via the Actos settlement if you or a loved one used an Actos-related medication prior to December 1, 2011, and were diagnosed with bladder cancer. To learn if you are eligible to participate in Takeda’s settlement program, please contact Bernstein Liebhard LLP at (888) 994-5118.

Takeda Agrees to $2.37 Billion Settlement of Actos Bladder Cancer Claims

  • May 2015: Takeda Pharmaceuticals announced that it would settle thousands of Actos lawsuits for at least $2.37 billion. For the accord to take effect, 95% of plaintiffs would need to agree to participate in the settlement by September 11, 2015. According to Bloomberg News, plaintiffs who sign on to the agreement would be eligible for an award of more than $296,000 per case. However, the payment may be reduced depending on a patient’s age, smoking history and exposure to toxins. Read More
  • August 2015: The Actos settlement appeared to be in jeopardy, as only 75% of eligible plaintiffs have signed on to the accord. According to Bloomberg News, large verdicts in Actos trials may be behind the reluctance of some plaintiff to participate.
  • September 2015: The Actos bladder cancer settlement is finalized, after 96% of eligible claimants agree to the accord. Takeda also announced that the total settlement will rise to $2.4 billion if after a review of the claims submissions it is determined that 97% or more of them meet the settlement criteria.

Significant Actos Verdicts

  • April 2014: The first Actos bellwether trial ends with the plaintiff awarded more than $9 billion in punitive and compensatory damages. Not only did jurors find that Takeda and Eli Lilly & Co. concealed the risk of bladder cancer associated with Actos, they also determined that the companies had “acted with wanton and reckless disregard” for patients’ safety. In October, however, the judge presiding over the case reduced the award to $36.8 million, “the maximum amount a jury could have properly awarded” under current U.S. law.
  • September 2013: The nation’s second Actos trial ends with a Maryland jury awarding $1.7 million to the family of a man who died as a result of bladder cancer the previous year. However, the presiding judge throws out the verdict in accordance with Maryland law because the jury also found that the decedent’s 30-year smoking habit contributed to the development of the disease. Read More
  • April 2013: The first Actos trial involving bladder cancer allegations ends after a California Superior Court jury finds that Takeda failed to warn consumers that Actos could cause bladder cancer. The plaintiff and his wife are awarded $6.5 million in compensatory damages. A month later, the judge overseeing the trial reverses the verdict, after finding that that the plaintiff’s medical expert had failed to establish that Actos was the specific cause of his cancer. In July 2015, the verdict was reinstated by the California Court of Appeal.

Do You Have an Actos Lawsuit?

You may be eligible to file a lawsuit against Takeda if you were diagnosed with bladder cancer after using Actos to treat Type 2 diabetes. To learn more about the Actos settlement, and to arrange for a free, no-obligation review of your case, please call (888) 994-5118.

  1. Bloomberg News (2015) “Takeda Agrees to Pay $2.3 Billion to Settle Actos Cases
  2. Bloomberg News (2015) “Takeda’s $2.37 Billion Diabetes Drug Accord Endangered”
  3. FiercePharma (2015) “Takeda gets enough takers to complete $2.3B Actos settlement”
  4. Bloomberg News (2014) “Takeda, Lilly Win 99.6% Cut in Actos Punitive Damages”
  5. Law360 (2015) “5M Takeda Verdict Reinstated in 1st Actos Trial”
Last Modified: February 23, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest